Industry Highlights: Switching From Manual To Automated HSC Gene Engineering

Automating hematopoietic stem cell manufacturing can help address some of the biggest barriers facing gene therapy production: scalability, variability, contamination risk, hands-on time, and GMP alignment. See how CD34+ cell enrichment and HSC engineering can move from manual steps into a closed, automated workflow using the CliniMACS Prodigy, supporting cell isolation, culture, viral transduction, harvest, sampling, and downstream formulation. A perspective from Orchard Therapeutics adds practical insight into process comparison work, where automated manufacturing showed strong CD34+ enrichment, high viability, improved transduction efficiency, higher vector copy number, reduced lentiviral vector usage, and shorter manufacturing time.

For teams evaluating how to scale HSC gene therapy programs, get a useful look at both workflow design and real-world process optimization.